Cargando…
Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
SIMPLE SUMMARY: In stage IV melanoma, the combination of ipilimumab and nivolumab improves outcomes compared to single agents. However, it bears an important financial impact on the healthcare system. In this manuscript, we analyze the costs related to the ipilimumab–nivolumab combination, focusing...
Autores principales: | Gautron Moura, Bianca, Gerard, Camille L., Testart, Nathalie, Caikovski, Marian, Wicky, Alexandre, Aedo-Lopez, Veronica, Berthod, Grégoire, Homicsko, Krisztian, Prior, John O., Dromain, Clarisse, Kandalaft, Lana E., Cuendet, Michel A., Michielin, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817856/ https://www.ncbi.nlm.nih.gov/pubmed/36612030 http://dx.doi.org/10.3390/cancers15010031 |
Ejemplares similares
-
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma
por: Aedo-Lopez, Veronica, et al.
Publicado: (2022) -
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022) -
Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology
por: Krebs, Fanny S., et al.
Publicado: (2020) -
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient
por: Pillonel, Vincent, et al.
Publicado: (2019) -
First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer
por: Digklia, Antonia, et al.
Publicado: (2022)